CBD Shows an Early Signal in Smoking Reduction
Could cannabidiol (CBD) help people stop smoking? The evidence so far is intriguing but limited. A small 2013 pilot trial found that smokers who used a CBD inhaler smoked about 40% fewer cigarettes during one week of treatment than those who used a placebo inhaler. However, the study involved only 24 people, measured cigarette consumption rather than long-term abstinence, and was not designed to establish CBD as an effective cessation treatment.
The study, published in Addictive Behaviors, randomly assigned 12 smokers to receive a CBD inhaler and 12 to receive placebo. Participants used their assigned inhaler when they felt the urge to smoke. Cigarette consumption fell significantly in the CBD group during the treatment week, while the placebo group showed no comparable reduction. Some of the effect appeared to persist at follow-up, but the researchers described their findings as preliminary and called for larger studies.
The often-cited 40% figure therefore comes from the 2013 human trial—not from a 2023 study. The 2023 research examined a different question: whether CBD and its metabolite 7-hydroxy-CBD interfere with enzymes involved in nicotine metabolism. In laboratory experiments using human liver tissue and engineered cell systems, the compounds inhibited several enzymes, including CYP2A6, the main enzyme that converts nicotine into cotinine. The results suggest a possible biological mechanism, but they do not show that CBD helps people quit smoking.
Slowing nicotine metabolism could theoretically allow more nicotine to remain in the bloodstream after each cigarette, potentially reducing the number of cigarettes needed to maintain nicotine levels. That explanation remains hypothetical in humans. The 2023 study was not a clinical cessation trial, did not test whether participants smoked less or quit, and did not establish a safe or effective dose of CBD for tobacco dependence.
CBD is generally considered non-intoxicating, unlike THC, but “non-intoxicating” does not mean risk-free. The U.S. Food and Drug Administration warns about potential liver injury and drug interactions associated with CBD products. CBD may alter how other medicines are metabolized, and over-the-counter products can vary in strength and purity. Anyone taking prescription drugs, managing liver disease, or who is pregnant or breastfeeding should discuss CBD with a healthcare professional before using it.
CBD also should not be presented as a safer replacement for established cessation therapies without qualification. Nicotine replacement therapy delivers controlled doses of nicotine without the toxic chemicals produced by burning tobacco; it is intended to reduce withdrawal symptoms while a person moves away from cigarettes. The Centers for Disease Control and Prevention recommends evidence-based medications and counseling, including nicotine patches, gum, lozenges, prescription inhalers or nasal spray, varenicline, and bupropion. Combining counseling with medication gives adults who smoke a better chance of quitting than relying on either approach alone.
For now, CBD is best regarded as an experimental possibility rather than a proven nicotine-cessation aid. The available research points to a small preliminary smoking-reduction signal and a laboratory mechanism worth investigating, but it does not demonstrate sustained abstinence, confirm benefits from commonly sold CBD products, or show that CBD is superior to approved treatments. People trying to quit should consult a healthcare professional or call 1-800-QUIT-NOW for free cessation support before adding CBD to a quit plan.
